GI
IPHA

GAMMA Investing’s Innate Pharma IPHA Stock Holding History

GAMMA Investing’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Sell
9
-231
-96% -$382 ﹤0.01% 4130
2026
Q1 		$307 Sell
240
-833
-78% -$1.36K ﹤0.01% 4020
2025
Q4 		$1.88K Sell
1,073
-1,208
-53% -$2.33K ﹤0.01% 3621
2025
Q3 		$4.4K Sell
2,281
-1,175
-34% -$2.36K ﹤0.01% 3226
2025
Q2 		$6.27K Buy
3,456
+1,223
+55% +$2.48K ﹤0.01% 3029
2025
Q1 		$3.98K Buy
+2,233
New +$4.36K ﹤0.01% 3174

Other funds holding IPHA

SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing's IPHA Position: Q2 2026 in Review

GAMMA Investing reduced its Innate Pharma (IPHA) stake by 96% in Q2 2026, selling an estimated $382 and leaving 9 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #4130.

GAMMA Investing first reported a position in IPHA in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.27K in Q2 2025. 3 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

  • GAMMA Investing held 9 shares of Innate Pharma worth $17 as of Q2 2026.
  • GAMMA Investing sold 231 Innate Pharma shares in Q2 2026, an estimated $382.
  • Innate Pharma made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4130 holding.
  • GAMMA Investing first reported a position in Innate Pharma in Q1 2025 and has held it in 6 quarters since.
  • GAMMA Investing's Innate Pharma position peaked at $6.27K in Q2 2025.
  • 3 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.